Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New Fluoroquinolones: Real and Potential Roles.

Ball1

  • 16, Gilchrist Row, St. Andrews, Fife KY16 8XU, Scotland.

Current Infectious Disease Reports
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of a Planned Change to Nurse Staffing Levels in Emergency Departments: A Pre-Test, Post-Test Design.

Journal of advanced nursing·2025
Same author

Angular structure of lacunarity, and the renormalization group

Physical review letters·2000
Same author

A prospective study of tracheopulmonary complications associated with the placement of narrow-bore enteral feeding tubes.

Critical care (London, England)·2000
Same author

Dynamical weight functions for a planar crack

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same author

Numerical investigation of the effects of classical phase space structure on a quantum system with decoherence

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same author

Momentum distributions for the quantum delta-kicked rotor with decoherence

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same journal

Chagas Disease: An Opportunistic Infection in AIDS.

Current infectious disease reports·2026
Same journal

Area-based Deprivation Indices and Healthcare-Associated Infections: A Narrative Review of Evidence.

Current infectious disease reports·2025
Same journal

Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays.

Current infectious disease reports·2024
Same journal

To Tweet or Not to Tweet-a Review of the Viral Power of Twitter for Infectious Diseases.

Current infectious disease reports·2024
Same journal

Web alert.

Current infectious disease reports·2024
Same journal

Bacterial Vaginosis in Postmenopausal Women.

Current infectious disease reports·2023
See all related articles

Third-generation fluoroquinolones offer improved efficacy against Gram-positive and anaerobic bacteria, addressing limitations of older drugs. These new agents show promise in treating respiratory and surgical infections, though differing side effect profiles require consideration.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Second-generation fluoroquinolones have a decade-long history of safe and effective clinical use.
  • Limitations exist regarding activity against Gram-positive and anaerobic organisms, restricting their use in certain infections.
  • These limitations necessitate the development of new antimicrobial agents.

Purpose of the Study:

  • To evaluate the efficacy and safety of third-generation fluoroquinolones.
  • To compare the activity of new fluoroquinolones against Gram-positive and anaerobic bacteria, including key pathogens like Streptococcus pneumoniae and Bacteroides fragilis.
  • To assess the role of these agents in treating respiratory, intra-abdominal, pelvic, surgical, and gynecologic infections.

Main Methods:

Related Experiment Videos

  • Clinical trials evaluating third-generation fluoroquinolones.
  • Microbiological studies assessing in vitro activity against relevant pathogens.
  • Comparative analysis of efficacy and adverse reaction profiles.

    • Main Results:

    • Third-generation fluoroquinolones demonstrate significantly enhanced activity against Gram-positive and anaerobic bacteria.
    • High efficacy rates were observed in pneumonia, bronchitis, and surgical/gynecologic infections.
    • While clinical outcomes are often similar, distinct adverse reaction profiles exist among the new agents.

    Conclusions:

    • Third-generation fluoroquinolones represent a significant advancement, overcoming the limitations of earlier generations.
    • These agents offer effective treatment options for a broader range of infections, particularly those involving Gram-positive and anaerobic pathogens.
    • Therapeutic selection may be influenced by the differing adverse event profiles of these novel fluoroquinolone drugs.